Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2020-12-04 Director's Dealing
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DiaSorin S.p.A. - Allegato 3F
Director's Dealing Classification · 99% confidence The document is a formal disclosure titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE" (Model Disclosure for Transactions in the Issuer's Securities) from DiaSorin S.p.A., dated December 4, 2020. Section 3 details 'OPERAZIONI' (Transactions) showing sales ('V' for Vendita) of the company's own shares (DiaSorin) totaling 57,000 units during November 2020. The context explicitly mentions these are sales of treasury shares following the exercise of stock options ("operazioni di vendita di azioni proprie a beneficiari del 'Piano di Stock Option'"). This directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), an annual report (10-K), or a management discussion (MDA), but a specific regulatory filing about share transactions.
2020-12-04 Italian
DiaSorin received FDA approval for its LIAISON XL MUREX HIV Ab/Ag assay
Regulatory Filings Classification · 99% confidence The document is a formal announcement from DiaSorin dated December 1, 2020, regarding receiving FDA approval for a new diagnostic assay (LIAISON® XL MUREX HIV Ab/Ag HT Assay). The metadata indicates it was received as 'REGEM' (Regulated Information) and the content is a press release detailing a significant business/product event. This type of announcement, which is not a standard periodic financial report (10-K, IR, ER) but rather a specific operational update concerning product regulatory milestones, fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory/material event disclosure, or potentially a general 'Capital/Financing Update' (CAP) if it were related to fundraising, but here it is product/regulatory news. Since it is a specific, material announcement that doesn't fit the other specific categories (like DIV, DIRS, MANG), RNS (Regulatory Filings) is the most appropriate fallback for a general regulatory announcement not covered elsewhere. It is not an Earnings Release (ER) or an Interim Report (IR).
2020-12-01 English
DiaSorin ha ricevuto l’approvazione a commercializzare il test LIAISON XL MUREX HIV Ab/Ag dalla Food and Drug Administration
Regulatory Filings Classification · 99% confidence The document is a formal announcement from DiaSorin, dated December 1, 2020, regarding receiving FDA approval to commercialize a new HIV test (LIAISON® XL MUREX HIV Ab/Ag HT). The metadata indicates the filing type as 'REGEM' (Regulated Information) and the content is a press release detailing a significant business/product development. This type of announcement, which is not a full financial report (10-K, IR), a specific shareholder vote result (DVA), or a management change (MANG), fits best under the general category for regulatory announcements or significant corporate news that doesn't fit a narrower financial disclosure category. Since it is a formal, regulated announcement ('Informazione Regolamentata'), and it is not an announcement *about* a report (RPA), the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for official corporate disclosures that are not strictly financial statements or proxy materials. The length (6545 chars) is substantial enough to be the primary disclosure, not just a link announcement.
2020-12-01 Italian
DiaSorin: North America growth drives up revenues and profitability in the first 9 months of 2020
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first 9 months of 2020 (9M 2020). It contains detailed financial statements, including revenue breakdowns by geography, EBITDA, EBIT, net profit, and net financial position, along with management's commentary on business performance and results. It is not a short announcement or a certification, but a substantive interim financial report. 9M 2020
2020-11-11 English
DiaSorin: la crescita del Nord America traina l’aumento di Ricavi e Redditività nei primi 9 mesi del 2020
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial report from DiaSorin S.p.A. covering the first 9 months of 2020. It includes comprehensive financial statements (Revenue, EBITDA, EBIT, Net Income, Net Financial Position, Free Cash Flow), detailed breakdowns by product line and geography, and management commentary on business performance. It is not a short announcement (it exceeds 40,000 characters) and contains substantive financial data, qualifying it as an Interim/Quarterly Report rather than a simple release or announcement. 9M 2020
2020-11-11 Italian
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients
Regulatory Filings Classification · 95% confidence The document is a formal announcement dated October 26, 2020, detailing the launch of a new product (LIAISON® SARS-CoV-2 Ag test) that has received CE Mark approval. The structure, including the 'Oggetto' (Subject) field, the date, and the content describing a significant business development (product launch/innovation), strongly suggests a regulatory disclosure. Since this is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a specific shareholder/management action, it falls under general regulatory announcements. Given the context of Italian regulatory filings (indicated by 'Informazione Regolamentata' and the Italian company context), and the lack of a more specific category like M&A (TAR) or Capital Change (CAP), the most appropriate general category for a significant, non-financial-result-focused regulatory disclosure is Regulatory Filings (RNS). It is not an RPA because it is the substance of the announcement, not just a notice that a report is available.
2020-10-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.